• Open Access

Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors



This article is corrected by:

  1. Errata: ERRATUM Volume 23, Issue 1, 224, Article first published online: 12 January 2009

  • Results described in this report were previously presented at the following meetings: 17th ECVIM-CA Congress, September 2007 Budapest, Hungary; 2007 Veterinary Cancer Society Annual Meeting Ft. Lauderdale, FL; Genes, Dogs & Cancer: Canine Cancer Conference, September 2006 Chicago, IL.

Corresponding author: Kevin A. Hahn, DVM, PhD, ACVIM (Oncology), 1035 NE 43rd Street, Topeka, KS 66617, USA; e-mail: drhahn87@gmail.com.


Background: Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT).

Hypothesis/Objective: To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.

Animals: Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT.

Methods: Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg/kg/d PO) or a placebo. Time-to-tumor progression (TTP), overall survival, objective response at 6 months, and toxicity were assessed.

Resulsts: Masitinib increased overall TTP compared with placebo from 75 to 118 days (P= .038). This effect was more pronounced when masitinib was used as first-line therapy, with an increase in the median TTP from 75 to 253 days (P= .001) and regardless of whether the tumors expressed mutant (83 versus not reached [P= .009]) or wild-type KIT (66 versus 253 [P= .008]). Masitinib was generally well tolerated, with mild (grade I) or moderate (grade II) diarrhea or vomiting as the most common adverse events.

Conclusions and Clinical Importance: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.